DLE和SLE患者血清中抗RPLP0抗体水平及临床意义  

The study on serum level and clinical significance of anti-ribosomal protein P0 antibody in DLE and SLE patients

作　　者：杜艳瑜 谭国珍[1] 叶瑞心[2] 陈娇霞[3] 

机构地区：[1]中山大学孙逸仙纪念医院皮肤科,广州市510120 [2]中山大学孙逸仙纪念医院放射科,广州市510120 [3]中山大学孙逸仙纪念医院内科,广州市510120

出　　处：《实用医学杂志》2014年第16期2588-2591,共4页The Journal of Practical Medicine

摘　　要：目的:了解盘状红斑狼疮(DLE)和系统性红斑狼疮(SLE)抗RPLP0抗体的表达水平,分析其与各临床表现和实验室指标的关系。方法:酶联免疫吸附法(ELISA)检测抗RPLP0抗体;直接免疫荧光(DIF)检测皮损部位的免疫复合物;常规方法检测自身抗体及补体。结果:健康对照组、DLE组、SLE组的抗RPLP0-IgG抗体的吸光度(A.U.)均值分别为:0.72±0.16,0.53±0.18和1.23±0.62。DLE组患者的抗RPLP0-IgG抗体与健康对照组相比差异无统计学意义(P>0.05),而SLE组高于DLE组和健康对照组(P<0.05)。SLE血清抗RPLP0抗体高水平组患者的关节炎、肾脏损害和特征性皮损的频率高于抗RPLP0抗体低水平组(P<0.05),而抗RPLP0抗体水平与其他临床表现、SLEDAI、CLASI评分无相关性(P>0.05)。结论:DLE患者与健康人血清抗RPLP0抗体水平无差异,SLE患者血清抗RPLP0抗体水平高于DLE患者,且与关节损害、肾损害及特征性皮损相关。Objectives To study the serum level and the clinical significance of anti-ribosomal protein P0 antibody in discoid lupus erythematosus（DLE） and systemic lupus erythematosus（SLE） patients. Methods Serum anti-RPLP0 IgG antibody of 18 DLE patients and 23 SLE patients were tested by Enzyme-Linked Immunosorbent Assay （ELISA）. Direct immunofluoreseence （DIF） was used to examined the immunoreaetants from skin lesion. Serum antibody and complement C3 were detected by conventional methods. Results Anti-ribosomal P0 antibody was higher in SLE patients （1.23 ± 0.62. mean ± SD） than in patients with DLE （0.53 ± 0.18, P〈0.001） and healthy controls （0.72 ± 0.16, P〈0.001）, but was no difference in the later two groups （P=0.5）. Among SLE patients , anti-ribosomal P0 protein antibody were much higher in patients with arthritis , nephritis and specific skin lesion than in those without these disorders （P〈0.05）. Anti-ribosomal P0 antibody was not associated with SLEDAI and CLASI（P=0.012）. Conclusions There is no difference of serum anti-ribosomal P0 antibodies between healthy controls and DLE patients. SLE patients have higher level of serum anti-ribosomal P0 antibody , specially in those with specific skin lesion.

关 键 词：盘状红斑狼疮 系统性红斑狼疮 皮肤损害 抗RPLP0抗体 

分 类 号：R593.241[医药卫生—内科学]